US8450078B2 - Portable coagulation monitoring device and method of assessing coagulation response - Google Patents
Portable coagulation monitoring device and method of assessing coagulation response Download PDFInfo
- Publication number
- US8450078B2 US8450078B2 US12/971,013 US97101310A US8450078B2 US 8450078 B2 US8450078 B2 US 8450078B2 US 97101310 A US97101310 A US 97101310A US 8450078 B2 US8450078 B2 US 8450078B2
- Authority
- US
- United States
- Prior art keywords
- blood
- coagulation
- plate
- sample
- response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 230000015271 coagulation Effects 0.000 title claims abstract description 72
- 238000005345 coagulation Methods 0.000 title claims abstract description 72
- 230000004044 response Effects 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000012806 monitoring device Methods 0.000 title description 2
- 210000004369 blood Anatomy 0.000 claims abstract description 102
- 239000008280 blood Substances 0.000 claims abstract description 102
- 230000033001 locomotion Effects 0.000 claims abstract description 27
- 230000003287 optical effect Effects 0.000 claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 230000008878 coupling Effects 0.000 claims abstract description 6
- 238000010168 coupling process Methods 0.000 claims abstract description 6
- 238000005859 coupling reaction Methods 0.000 claims abstract description 6
- 238000005259 measurement Methods 0.000 claims abstract description 6
- 238000012360 testing method Methods 0.000 claims description 21
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 19
- 108010073385 Fibrin Proteins 0.000 claims description 18
- 102000009123 Fibrin Human genes 0.000 claims description 18
- 229950003499 fibrin Drugs 0.000 claims description 18
- 230000007246 mechanism Effects 0.000 claims description 16
- 206010053567 Coagulopathies Diseases 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 12
- 238000006073 displacement reaction Methods 0.000 claims description 11
- 230000035602 clotting Effects 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 238000010200 validation analysis Methods 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000009102 absorption Effects 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000000704 physical effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 78
- 210000001772 blood platelet Anatomy 0.000 description 41
- 238000000576 coating method Methods 0.000 description 26
- 230000006870 function Effects 0.000 description 14
- 239000000306 component Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 208000014674 injury Diseases 0.000 description 11
- 230000008733 trauma Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000518 rheometry Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 208000027276 Von Willebrand disease Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 208000032371 Glanzmann thrombasthenia 1 Diseases 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 208000000392 Thrombasthenia Diseases 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000758 acidotic effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000007786 electrostatic charging Methods 0.000 description 1
- 238000004924 electrostatic deposition Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004137 mechanical activation Methods 0.000 description 1
- 230000010358 mechanical oscillation Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910002055 micronized silica Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008742 procoagulation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
- G01N2011/006—Determining flow properties indirectly by measuring other parameters of the system
- G01N2011/008—Determining flow properties indirectly by measuring other parameters of the system optical properties
Definitions
- the invention relates to a device, and method which allows rapid assessment of coagulation response. More particularly, the invention relates to such a device and method which provides extensive and complex information on coagulation response, including platelet function and fibrin polymerization to allow selection of appropriate treatment protocols, in particular for trauma induced coagulopathies but also for the diagnosis of hereditary or acquired abnormalities of coagulation, such as von Willebrand disease or hemophilias.
- coagulation The process by which the body prevents blood loss is referred to as coagulation.
- Coagulation involves the formation of a blood clot (thrombus) that prevents further blood loss from damaged tissues, blood vessels or organs.
- a blood clot thrombus
- This is a complicated process with a cellular system comprised of cells called platelets that circulate in the blood and serve to form a platelet plug over damaged vessels and a second system based upon the actions of multiple proteins (called clotting factors) that act in concert to produce a fibrin clot.
- clotting factors proteins
- Platelets serve three primary functions: (1) sticking to the injured blood vessel (a phenomenon called platelet adherence), (2) attaching to other platelets to enlarge the forming plug (a phenomenon called platelet aggregation), and (3) providing support for the processes of the coagulation cascade (molecules on the surface of platelets greatly accelerate several key reactions)
- the protein based system serves to stabilize the plug that has formed and further seal up the wound.
- the support role of the platelet to the coagulation cascade is provided, in part, by one of the components on the outside of a platelet, called phospholipids, which are required for many of the reactions in the clotting cascade.
- the goal of the cascade is to form fibrin, which will form a mesh within the platelet aggregate to stabilize the clot. All of the factors have an inactive and active form. Once activated, the factor will serve to activate the next factor in the sequence until fibrin is formed.
- the coagulation cascade takes place at the site of a break in a blood vessel that has the platelet aggregate. Fibrin forms a mesh that, in concert with the platelets, plugs the break in the vessel wall. The fibrin mesh is then further stabilized by additional factors which cross-linkup the clot (much like forming an intricate network of reinforced strands of fibrin).
- whole blood is meant a mixture of whole blood with one or more substances, a fraction of whole blood containing one or more of the constituents of whole blood, a fraction of whole blood mixed with one or more non-blood substances, or a purified blood constituent, such as blood platelets or serum, a reconstituted blood preparation, a modified blood sample, or a blood substitute.
- TEG Traditional TEG requires a relatively large sample of blood, i.e., about 0.36 ml in a small cup.
- a pin is inserted into the blood and is rotated in a sinusoidal oscillation through a small angle at a low frequency.
- the device measures coupling of motion through rotation over time. It does not measure platelet adhesion, only polymerization of fibrin, and does not allow for mechanical activation of the coagulation response through shear forces.
- the information obtained from a TEG analysis falls far short of our current understanding of coagulation response, and requires excessive amounts of time which could result in inappropriate treatment for trauma being applied, leading to adverse results to a patient, possibly even death.
- PFA-100 attempts to mimic a blood vessel by forcing blood flow through a narrow channel leading to a filter which has an aperture therein.
- the device measures the time for the aperture to clog and is essentially indicative of platelet function response which results in clogging.
- the time of closure of the aperture indirectly provides an indication of clotting due to platelet response.
- TEG and the PFA-100 requires intensive laboratory training and upkeep, and they are not easily used in the field.
- a portable coagulation monitoring device for diagnosis of trauma-related coagulopathies in the field, which yields rapid results, including extensive information about the complex mechanisms involved in coagulation, from a small sample of blood. More specifically, it is important to provide such a device which can be used by first responders under conditions encountered in the field, providing real time information, which allows for immediate treatment of a hemorrhaging event, as compared to prior art systems and devices which could result in delays of 45 minutes or more during what is considered an important initial time period for critical care to be applied and which use non-anticoagulated blood samples that do not have to be treated with activators and initiators as surrogates for the true coagulation process.
- the invention relates to a device for measuring coagulation response in a native, non-anticoagulated blood sample.
- the device includes two members or plates each having surfaces facing each other, and spaced an amount sufficient to allow a relatively small sample of blood to contact both surfaces at the same time without an air space between.
- the plates are movable relative to each other in a parallel and linear direction, and the spacing is such that the components of blood can initiate coagulation or adherence to each of the surfaces.
- a drive mechanism is connected to either one or both of the members for linearly moving one or the other relative to each other when a blood sample is in contact with their surfaces.
- An optical detection sensor system is provided for detecting interaction of light with a blood sample located between the two members, with the interaction of light and detection thereof providing an indication of coagulation response of the blood sample. More specifically, with appropriate positioning of light source and detectors, over time and in accordance with the variation of the movement of the members to generate a particular shear rate, information about both platelet response, fibrin response and other responses of the blood components during coagulation can be obtained.
- the device allows for the measurement of coagulation response based on the knowledge that the biophysical response of blood depends in part on the relative shear rate between the blood and surfaces with which it is in contact. More specifically, the higher the shear rate, the greater the platelet response so that the platelets then stick to the surfaces of the plates, and thereby trigger the fibrin polymerization and couple the motion of the two plates when only one is driven by the motors. More specifically, it is recognized that in hemorrhaging events platelets need to react quickly so the use of a high shear rate for a short time period can allow accurate assessment of platelet response for these conditions. Thereafter, lower shear rates can be employed in terms of relative movements of the plates or members with respect to each other, to obtain an accurate assessment of fibrin response, or at an intermediate shear rate, both fibrin and platelet response.
- Shear here is defined as the acceleration force felt by a particle in the moving bulk flow of fluid (blood) at the interface with the stationary solid (face of the glass plates).
- the shear “rate” is the differential of velocities felt on different aspects of the particle's cross-sectional area and is dependant on the particle's distance from the stationary surface.
- the first member and second members are plates making up a blood sample collection cartridge which is removable from the device.
- the device is programmed for moving the plates at different speeds relative to each other for detecting different mechanisms involved in a coagulation response of a blood sample, as previously discussed with respect to shear.
- the optical detection system is adapted for detecting binding of the blood sample to the surfaces to couple the motion of the plates relative to each other as an indication of platelet response during coagulation.
- the system can also probe fibrin response.
- a method of measuring coagulation response in blood sample A sample droplet of blood is placed between and in contact with facing surfaces of oppositely disposed plates. At least one or both plates are moved linearly with respect to the other at a predetermined rate. The coagulation response of the droplet is optically detected.
- the plates can be moved relative to each other at a first speed and a response optically detected, and thereafter moved at a second speed which is slower than the first speed and a second response optically detected, typically fibrin polymerization.
- the visco-elastic response of the blood sample on the surfaces of both plates can cause the movement of the first plate to induce movement of the second plate (“coupled motion”), which can be measured as indicative of visco-elastic response of the blood, ultimately leading to conclusions which may be inferred relative to coagulation response.
- coupled motion can be measured as indicative of visco-elastic response of the blood, ultimately leading to conclusions which may be inferred relative to coagulation response.
- changes in the strain rates and visco-elastic state of the blood sample may be measured as a clot is formed, which is also indicative of coagulation response.
- Optical detection may be done by transmitting light into the sample droplet, and detecting at least one of transmission, reflection and refraction of the light through the sample droplet at respective light detectors.
- Analog signals may be generated from the detection representative of coagulation properties of the blood in the sample droplet.
- the plates are preferably made of glass, more specifically transparent glass, to allow light transmission of 90% or more of the incident light intensity.
- FIG. 1 is a schematic diagram illustrating various components making up the device and system in accordance with the invention.
- FIG. 2 is a schematic diagram of a sample cassette in which a sample droplet may be loaded, and which may be employed in an exemplary embodiment of the portable coagulation monitor in accordance with the invention, for example, as shown in FIG. 1 .
- FIG. 3 in a schematic diagram illustrating relative movement of two plates in contact with blood to cause shear and initiate clottING response
- FIG. 4 is a perspective view of an embodiment of the device of the invention.
- FIG. 5 is an exploded view of an embodiment of the device of the invention.
- FIG. 1 illustrates in schematic form an exemplary portable coagulation monitor or assay device 11 for diagnosis of trauma or other related coagulopathies in which it is important to assess coagulation response to optimize treatment, for example, in critical field situations wherein the first hour is critical in terms of preventing long-term debilitating events or even death.
- the device is housed in an impact resistant housing 13 which has all the components housed thereon in a conventional manner.
- At least one and preferably a pair of linear voice coil actuator motors 15 and 17 are provided for driving movement of sample plates in a removable blood sample cassette which is illustrated in greater detail in FIG. 2 . While the motors 15 and 17 and removable blood sample cassette 19 have been described briefly, the remaining components are discussed generally with reference to the drawings in a clockwise manner beginning with the data card port 21 in the upper left-hand corner of the device.
- the data card port 21 is useful for receiving an FD card or any memory module, including data on the module for calibrating the device 11 , and/or for removing data from the device 11 for input into another system in which the data can be analyzed.
- a USB port 23 allows for direct interface with a computer, for example, under the control of a physician for a more complex analysis.
- Microcontroller 25 operates with EEPROM 26 and handles data from the USB port and the data card port 21 and can provide control for a user interface (not shown) such as an LCD display which provides initially acquired data and analysis thereof to a user using the device.
- a user interface such as an LCD display which provides initially acquired data and analysis thereof to a user using the device.
- Linear voice coil actuator motors 15 and 17 , and the removable blood sample cassette 19 have been briefly described and will be discussed in greater detail hereinafter.
- a wireless link 27 such as for transmitting data in the RF or IR spectrum, is also provided, and provides an additional means for communicating data and programming to and from the device.
- Optical displacement sensors 29 and 31 detect where the linear voice coil actuator motors 15 and 17 are located and control the limits of movement thereof.
- the digital synthesizer module 33 serves to control operation of the motors 15 and 17 through motor drivers 35 by generating the necessary waveforms to drive the voice coil actuator motors 15 and 17 .
- the ADC module 37 is an analog to digital converter which obtains data from the optical or physical measurements conducted on a sample in the removable blood cassette 19 , converts the data into digital form and supplies it to microcontroller 39 which manages the data obtained to provide useful results to a user of the device.
- a 3-axis accelerometer 41 is a conventional device which takes into account outside effects and vibrations on the device 11 , and serves to cancel the effects of these vibrations on any data collected as a result of analysis of a sample.
- the removable blood sample cassette 19 is shown in FIG. 2 in schematic form and includes an upper sample plate 101 and a lower sample plate 103 between which can be deposited a sample droplet of blood.
- Linkages 105 to the voice coil actuator motors on the device are provided, which are connected to an upper linear compliant mechanism 107 and a lower linear compliant mechanism 109 which serve to drive movement of the upper and lower plates respectively.
- Optical sensors 111 are provided in position relative to the sample plates for detecting light being projected from, for example, a laser or other light source (not shown), through and into a sample between the plates. The light can then be detected as light transmitted through the sample, reflected, refracted or otherwise modified in the path through the sample, and detected by optical sensors 111 to obtain information about the coagulation properties of the blood sample.
- a power link 113 serves for connection to a power supply such as, for example, batteries or other form of power.
- a data link 115 can also be provided to allow data collected from the sample and stored on an EEPROM 117 to be downloaded from the device.
- the data link 115 and EEPROM 117 when the cassette 19 is received in the device 11 , can be connected to the various electronic components within the device 11 for having data uploaded and downloaded thereto.
- FIG. 4 further illustrates in assembly view, a device 11 in accordance with the invention showing various components thereof.
- the device is pocket-sized, preferably with overall dimensions similar to an iPhone, of about 12 cm by about 6 cm by about 2 cm.
- the device 11 is ruggedized with an internal accelerometer compensating for impacts and vibration. As designed it is versatile and can measure platelet and fibrin clotting over a wide dynamic range of shear. Yet still further, the device 11 can operate on USB hub power as a peripheral device with components which are readily manufactured and assembled. Typically, biophysical resolution is less than about 2 ⁇ displacement, and the device 11 allows for a wide range of shear stresses and complete optical access.
- the device 11 preferably is made of a monolithic CNC-machined housing, of materials such as Acetal, 6A1-4V Ti, 2024 A1.
- a bottom sample window 203 cooperates with a top sample window 205 and they are moved by displacement sensor arms 207 .
- a monolithic compliant four-bar mechanism 209 made typically of aluminum is associated with the displacement sensor arms 207 .
- Motor assemblies 211 typically a VCA motor coil assembly, serves to move the various components and is associated with a magnet assembly 213 , typically made of rare earth.
- Optical sensor arrays 215 serve to interrogate and measure the clotting response.
- the sensor arrays 215 are typically infra-red differential displacement sensor arrays.
- the first and second surfaces of the plates 101 and 103 have, at least, been coated with textures, substances or other materials to induce, slow or otherwise modify the coagulation process so as to select for or against specific aspects of coagulation of the sample for diagnostic or other purposes.
- Modification to the surfaces can include those that enhance platelet or blood protein binding reactivity or activation. Similarly, such modification can reduce platelet or blood protein binding reactivity, or activation as will become more clearly evident from the following detailed discussion of such treatments or coatings.
- the device is capable of analyzing blood rheology and coagulation of fresh whole blood or some fraction thereof without the need to add external reagents, such as tissue factor, kaolin, initiator, citrate and others. Such substances and others may electively be added for detailed analytical reasons, but in the most desired embodiment of the device, they are not necessary.
- the device 11 is configured for measuring in real time or with minimal delay the dynamic balance between pro and anti thrombotic hemostatic status by sequential samples from the same person or animal.
- the motors 15 and 17 are linear voice coil actuator motors, but can be any other type of device capable of driving linear motion.
- detection of coagulation is done optically by measuring mechanical interaction between the first and second surfaces of the plates 101 and 103 resulting from changes in the viscosity of the sample fluid and binding to the plate surfaces.
- the relative motions between the two plates 101 and 103 is controlled to generate arbitrarily selected wave forms to induce desired fluid shear rates at selected amplitudes, frequency, duration, and sequence such that the device is enabled to emulate fluid shear as desired over a very broad range, from DC (zero shear) to shear rates that would cause fluid cavitation and subsequent destruction of the cellular components of the sample, and continuously including all points in the shear rate spectrum between these two points.
- the shear rate is controlled in a sequence of values to generate specific protocols or plate motion paradigms for targeted diagnostic or analytic objectives, such as rapid initiation of primary coagulation, destructive or non-destructive viscoelastic evaluation of early, mid-phase, or late-phase clotting, emulation of clinically accepted or otherwise recognized shear rate protocols for comparison with other commercial or experimental devices, or validation testing against known standards. While light can be used for optical detection it is clear that the full electromagnetic spectrum of waves can be used to generate analog signals representative of coagulation properties of the sample droplet for both primary and secondary coagulation mechanisms.
- blood sample when used herein, it is intended to mean whole blood, a mixture of whole blood with one or more substances, a fraction of whole blood containing one or more of the constituents of whole blood, a fraction of whole blood mixed with one or more non-blood substances, or a purified blood constituent, such as blood platelets or serum, a reconstituted blood preparation, a modified blood sample, or a blood substitute.
- interchangeable sample cassettes 19 can be employed, each one serving a different analytical and maintenance or calibration function.
- One cassette 19 can be for regular calibration and validation of the device 11 .
- such a disposable and replaceable cassette 19 can serve to calibrate the device 11 , receive the blood sample, hold the blood sample, allow different sample chamber geometries for different test protocols, maintain sample the viability during a test, serve for safe removal of the sample for storage such a freezing, freeze drying, etc., or for sample disposal without exposure to the blood sample.
- the cassette 19 allows for collection of the blood sample by means of simple capillary action eliminating the need to use sample extraction and metering devices.
- cassettes 19 may be manufactured for different tests and applications with different sample plate spacings, different surface chemical and optical properties, and similar variations for analysis and validation testing.
- the cassette 19 may contain optical interrogation electronics allowing detection of blood status, type, pH, oxygenation, metabolites, toxins, or other measures detectable by optical means.
- the device 11 is such that through its electronics it can be interfaced with other laboratory systems such as microscopes, etc.
- the plates 101 and 103 are preferably optically clear to allow optical signals to pass through the blood sample allowing direct optical visualization of a portion or all of the blood sample between the planar surfaces. This allows transmission, reflection, internal reflection, selective absorption, polarization or optical rotation, frustrated internal reflection (either partial or total), and conduction of laser beams or other light surfaces.
- the cassette 19 may contain a non-volatile permanent memory storage device such as EEPROM 117 , for containing initial data that identifies the cassette, lot, manufacture date, and details of construction, as well as allowing for storage of key data such as user-defined sample identification information, test initiation time, test duration, and specified test output data and results, to be permanently stored with each sample until destroyed.
- EEPROM 117 non-volatile permanent memory storage device
- the cassettes 19 may contain additional fluids or other materials such as additives, preservatives, sealing or barrier agents, and other like agents which can be added to or layered on top of the blood sample before, during, or after testing.
- additional fluids or other materials such as additives, preservatives, sealing or barrier agents, and other like agents which can be added to or layered on top of the blood sample before, during, or after testing.
- rotary motion can be used to induce shear in addition to or as a replacement for linear displacement previously discussed.
- the device 11 is capable of delivering mechanical shear to the blood sample over a wide dynamic range of mechanical oscillations, including 0.0001 Hz to 1000 Hz employing a digital synthesizer 33 previously disclosed, typically a dual channel synthesizer, with the ability to generate regular periodic waveforms such as sine waves, triangle waves, square waves of varying duty cycle, frequency, and amplitude, plus the ability to generate arbitrary waveforms with rapid changes in all parameters, such as slew rate, amplitude, etc., or which may also hold steady (DC) mechanical displacements of either one or both of the planar surfaces.
- a digital synthesizer 33 typically a dual channel synthesizer, with the ability to generate regular periodic waveforms such as sine waves, triangle waves, square waves of varying duty cycle, frequency, and amplitude, plus the ability to generate arbitrary waveforms with rapid changes in all parameters, such as slew rate, amplitude, etc., or which may also hold steady (DC) mechanical displacements of either one or both of the planar
- the motors 15 and 17 may be driven by drivers 35 in a manner where either one or both drive mechanisms are coupled with the motors 15 and 17 , and can be employed simultaneously to effect linear motion, or where either may be employed as a single or in concert with the other mechanism serving as a precision sensor for mechanical displacement.
- mechanical features are incorporated such as 4-bar of multi-bar monolithic compliant mechanisms, to eliminate mechanical hysteresis from the use of sliding or rolling bearing surfaces other than those associated with the blood sample itself.
- Data analysis and reduction software may be incorporated into the device electronics to allow the resulting measured parameters of blood coagulation to be stored for later retrieval, transferred to a computer or other device for display, storage, or analysis, displayed graphically, displayed in numerical form with physical units, or displayed in icon or symbolic form to indicate a specific diagnosis, clinical indication, or parametric change of clinical significance.
- the software will allow the resulting data to be represented in such a way to allow the user to compare the results directly with similar or analogous results that would be expected from other devices with similar functions, or to display the data in such a way to render comparison with accepted standard values or ranges for coagulation parameters.
- a user interface (not shown) is implemented with the device such as a LCD user interface.
- the device 11 employs plates 101 and 103 motion protocols coupled with data analysis and data reduction software to enable the direct assessment of, for example, platelet function, function of the coagulation cascade, red blood cell (RBC) rheology, RBC aggregation, the effects of pro- or anti-coagulation agents, fibrinolysis, and other characteristics of blood coagulation.
- the device 11 with appropriate user requirements and user interfaces may be classified as “simple” (CLIA “waived” classification) to permit use in-home and by unskilled users.
- the disposable cassette is configured for collecting and holding the blood sample through simple unskilled collection of the fluid sample without requiring the use of any measuring pipette, syringe, or other metering device for blood sample collection.
- the cassette 19 allows safe handling, storage, retrieval, and disposal of the collected blood sample and may be manufactured to allow adjustment of the surface area and spacing between the plates to allow the use of very small volumes of blood, typically on the order of less than about 1 mL.
- the device 11 and cassette 19 allows optical microscopic inspection of most or all of the sample volume before, during, or after coagulometric analysis, using both standard and inverted microscopic arrangements.
- the device 11 can be employed to diagnose and quantify diseases and derangements of blood coagulation, including but not limited to induced, acquired, and congenital conditions such as trauma-induced coagulopathies (TIC), von Willebrand Disease (vWD), coagulation factor consumption, platelet consumption, thrombasthenia, platelet metabolic exhaustion, hemodilution, over-activation of protein C, S, and fibrinolytic pathways, altered RBC rheology, and improperly administered coagulation modulating therapeutics, and other diseases and conditions of blood coagulation.
- TIC trauma-induced coagulopathies
- vWD von Willebrand Disease
- coagulation factor consumption platelet consumption
- thrombasthenia platelet metabolic exhaustion
- hemodilution over-activation of protein C, S, and fibrinolytic pathways
- the device 11 can rapidly assess coagulopathies in the field in a period of time less than 15 minutes, and preferably less than 4 minutes, at the site of an injury or trauma, during transport, or at any other time during the course of rescue, first response, treatment, surgical intervention, or recovery.
- Use of feedback and feed-forward technology serves to stabilize the blood sample to resist the effects of external mechanical noise, vibration, and shock from impact. Testing the time course of changes in both primary and secondary coagulation during the early phase of medical response to trauma and blood loss can be effected. Similarly, intra-surgical testing of primary and secondary coagulation, and changes to these mechanisms during the course of surgery can be accomplished.
- the device 11 can be used for rapid in-vitro screening of bioactive compounds intended to affect the mechanisms of primary or secondary coagulation. It can also be used for guidance of clinical treatment of diseases of the mechanisms of primary or secondary coagulation.
- the device 11 and cassette 19 may be modified for use in the measurement of the rheological properties of other bodily substances of clinical and research interest, such as pulmonary mucous, for the study of and clinical guidance of the treatment of cystic fibrosis, for example, such applications requiring a specially-designed cassette (disposable) and specialized test protocols and firmware, or for use in the study of new and novel fluids with variable rheology.
- the device 11 employs opto-electronic and wireless means to allow more than one device to be employed simultaneously, or with multiple samples, each with different test initiation times and different test durations or different sample chamber test protocols, to provide a rich set of coagulation data to a central computer or data collection and display device. This allows that many samples can be monitored simultaneously to track dynamic changes in the coagulation status of blood from an individual during surgery or recovery, or during transport or treatment in the field.
- certain embodiments of the invention may take the form of adding coatings to the plates 101 and 105 , typically glass plates, on the surfaces that come into contact with the blood sample.
- These coatings may be of a character to promote platelet adherence and activation, such as collagen, more specifically type IV collagen, of human or bovine origin.
- the coating may be derived from the extracellular matrix (ECM) of cultured fibroblasts, or from cultured endothelium, or derived from the natural subendothelial tissue of living blood vessels of human or animal origin.
- ECM extracellular matrix
- Particular molecular components of the matrix, such as vitronectin or fibronectin may comprise the coating or be an enriched feature of the matrix to enhance the adhesion properties.
- the coating may also be of a synthetic nature to promote platelet adherence and/or activation, such as polyamides or polyglucosamines, more specifically ⁇ -N-acetyl polyglucosamine of natural or synthetic origin.
- Other embodiments may incorporate coatings on the plates 101 and 105 to modulate platelet function, such as materials capable of releasing activators of platelet function, e.g., adenosine diphosphate or epinephrine, or inhibitors of platelet function such as prostaglandins, e.g., prostacyclin or prostaglandin E-1.
- Another embodiment of the invention may take the form of adding coatings to the plates 101 and 105 that promote, initiate, or modulate the process of coagulation and fibrin polymerization.
- These coatings may take the form of materials capable of releasing micronized silica, or kaolin, or tissue factor (natural or recombinant), or other such agents which are known to promote steps in the coagulation cascade.
- the coatings may also be of a nature to reverse anticoagulants that may be present in the blood sample, such as a material capable of releasing the enzyme heparinase to remove heparin, or mineralized calcium to reverse citrate.
- coatings may be preferred for testing of blood from patients that do not have sufficient platelet count or function to be able to initiate coagulation by the shear-induced mechanism of platelet activation.
- the coatings may incorporate a source of phospholipids, either of natural or synthetic origin, or contain partial or whole thromboplastins to mimic the agents used in standard clinical coagulation tests such as the prothrombin time (PT) or partial thromboplastin time (PTT).
- PT prothrombin time
- PTT partial thromboplastin time
- coatings may be added to the plates that inhibit or modulate or reverse the effects of hyperfibrinolysis in the blood sample, such as materials capable of releasing epsilon amino caproic acid (EACA), or trans-examic acid, or aprotinin, or other antiplasmin compounds or chemicals that affect the action of the enzyme plasmin.
- EACA epsilon amino caproic acid
- aprotinin or other antiplasmin compounds or chemicals that affect the action of the enzyme plasmin.
- These coatings may be preferred for testing of blood from patients in a severe state of hyperfibrinolysis that obfuscates the ability to extract other useful information on the coagulation/hemostasis system components in the sample (and thus the patient) unless the immediate effects of plasmin in the test system are ablated.
- the coatings may contain buffering compounds of acidic or basic nature to adjust the blood sample pH to the optimal desired level of between pH 7.2 to 7.4 or other specified level to avoid loss of information when the sample is overly acidotic or basic due to severe conditions in the patient.
- buffering compounds may take the form of released salts or amino acids or other zwitterionic polymeric soluble compounds biocompatible with blood for the purpose of producing and maintaining the desired pH.
- these and other coatings to be added to the plates 101 and 105 of the instant invention generally do not alter the geometry of the blood sample space between the plates 101 and 105 , or the motion and control of the plates 101 and 105 by the motorized mechanism, beyond the capacity of the system to be adjusted to maintain the required gap within specifications.
- the preferred methods of manufacturing these coatings on the glass plates may include use of electrostatic charging and deposition of the desired materials directly in contact with the glass members, or by layering of thin molecular hydrogels and carrier emulsions containing the desired agents in a releasable form suitable for activation immediately when contacted by the blood sample.
- the specified coatings may be comprised of single agents for a singular purpose, or may be a combination mixture of several or more of the specified coatings for multiple supporting purposes.
- One embodiment may be comprised of having different coatings on the two surfaces, one of one type and the other of a different type or at different density or modification of the similar coating on the opposing member.
- one or more coatings may be applied at differing densities or concentration in differing areas of one or both surfaces, or with linear, radial, or other gradients of density of coating on one or both surfaces.
- the pattern or gradient for each coating type may differ from that of other surface coating treatments on the same or opposing surfaces. While in one exemplary embodiment the surfaces are glass, they may be of any other material capable of accepting the coatings thereon, and of functioning in the manner intended, as will be evident to those of ordinary skill.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (16)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/971,013 US8450078B2 (en) | 2009-12-18 | 2010-12-17 | Portable coagulation monitoring device and method of assessing coagulation response |
US13/897,712 US9063161B2 (en) | 2009-12-18 | 2013-05-20 | Portable coagulation monitoring device for assessing coagulation response |
US14/717,117 US10739358B2 (en) | 2009-12-18 | 2015-05-20 | Portable coagulation monitoring devices, systems, and methods |
US16/990,661 US11768210B2 (en) | 2009-12-18 | 2020-08-11 | Portable coagulation monitoring devices, systems, and methods |
US18/467,541 US20240069043A1 (en) | 2009-12-18 | 2023-09-14 | Portable coagulation monitoring devices, systems, and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28778009P | 2009-12-18 | 2009-12-18 | |
US12/971,013 US8450078B2 (en) | 2009-12-18 | 2010-12-17 | Portable coagulation monitoring device and method of assessing coagulation response |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/897,712 Division US9063161B2 (en) | 2009-12-18 | 2013-05-20 | Portable coagulation monitoring device for assessing coagulation response |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110151491A1 US20110151491A1 (en) | 2011-06-23 |
US8450078B2 true US8450078B2 (en) | 2013-05-28 |
Family
ID=44151642
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/971,013 Active 2031-02-15 US8450078B2 (en) | 2009-12-18 | 2010-12-17 | Portable coagulation monitoring device and method of assessing coagulation response |
US13/897,712 Active US9063161B2 (en) | 2009-12-18 | 2013-05-20 | Portable coagulation monitoring device for assessing coagulation response |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/897,712 Active US9063161B2 (en) | 2009-12-18 | 2013-05-20 | Portable coagulation monitoring device for assessing coagulation response |
Country Status (17)
Country | Link |
---|---|
US (2) | US8450078B2 (en) |
EP (1) | EP2513647B1 (en) |
JP (1) | JP5655091B2 (en) |
CN (1) | CN102687009B (en) |
AU (1) | AU2010330861B2 (en) |
BR (1) | BR112012014421B8 (en) |
CA (1) | CA2780492C (en) |
CO (1) | CO6551732A2 (en) |
CR (1) | CR20120326A (en) |
EC (1) | ECSP12011981A (en) |
ES (1) | ES2543099T3 (en) |
HK (1) | HK1173497A1 (en) |
HN (1) | HN2012001269A (en) |
MX (1) | MX2012007084A (en) |
NI (1) | NI201200109A (en) |
PE (1) | PE20121723A1 (en) |
WO (1) | WO2011075614A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015073941A1 (en) | 2013-11-15 | 2015-05-21 | Entegrion, Inc. | Portable coagulation monitoring devices, systems, and methods |
US9816955B2 (en) | 2011-12-26 | 2017-11-14 | Panasonic Healthcare Holdings Co., Ltd. | Liquid sample measuring system and measuring device |
US10739239B1 (en) * | 2013-10-28 | 2020-08-11 | Ifirst Medical Technologies, Inc. | Rotating magnetic disc medical analyzer and coagulation profiler |
US11378507B2 (en) * | 2016-11-15 | 2022-07-05 | Haemograph Pty Ltd. | Rheometer and method for the use thereof |
US20240069043A1 (en) * | 2009-12-18 | 2024-02-29 | Entegrion, Inc. | Portable coagulation monitoring devices, systems, and methods |
US12019041B2 (en) | 2018-11-20 | 2024-06-25 | Xatek, Inc. | Portable dielectric spectroscopy device |
US12277814B2 (en) | 2020-01-29 | 2025-04-15 | Ifirst Medical Technologies, Inc. | Medical analyzer and diagnostic sample profiler |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7892188B2 (en) * | 2003-10-22 | 2011-02-22 | Hemosonics, Llc | Method and apparatus for characterization of clot formation |
US8448499B2 (en) | 2008-12-23 | 2013-05-28 | C A Casyso Ag | Cartridge device for a measuring system for measuring viscoelastic characteristics of a sample liquid, a corresponding measuring system, and a corresponding method |
US20110142885A1 (en) | 2009-09-16 | 2011-06-16 | Velico Medical, Inc. | Spray-dried human plasma |
US10739358B2 (en) | 2009-12-18 | 2020-08-11 | Entegrion, Inc. | Portable coagulation monitoring devices, systems, and methods |
ES2739038T3 (en) | 2010-04-08 | 2020-01-28 | Hemosonics Llc | Display of hemostatic parameters |
US20140083628A1 (en) | 2012-09-27 | 2014-03-27 | Velico Medical, Inc. | Spray drier assembly for automated spray drying |
BR112013020675B1 (en) | 2011-02-15 | 2022-01-25 | Hemosonics, Llc | Devices and method for hemostasis assessment |
AU2012364909B2 (en) | 2011-02-15 | 2016-11-24 | Hemosonics, Llc | Characterization of blood hemostasis and oxygen transport parameters |
WO2012159021A2 (en) | 2011-05-19 | 2012-11-22 | Hemosonics, Llc | Portable hemostasis analyzer |
CA2898201C (en) | 2012-01-16 | 2023-09-26 | Abram Scientific, Inc. | Methods, devices, and systems for measuring physical properties of fluid |
EP2926115B1 (en) | 2012-11-30 | 2021-05-26 | The University of North Carolina At Chapel Hill | Methods and systems for determining physical properties of a specimen in a portable point of care diagnostic device |
EP2932250B1 (en) * | 2012-12-17 | 2017-10-04 | Abbott Point Of Care, Inc. | Self correction for spatial orientation and motion of portable clinical testing devices |
WO2014099419A1 (en) | 2012-12-17 | 2014-06-26 | Abbott Point Of Care Inc | A portable clinical analysis system for hematocrit measurement |
EP2932259B1 (en) | 2012-12-17 | 2019-11-13 | Abbott Point Of Care, Inc. | Spatial orientation determination in portable clinical analysis systems |
CN104956222B (en) | 2012-12-17 | 2018-10-02 | 雅培医护站股份有限公司 | The operation and verification of Portable Clinical analysis system |
US9885706B2 (en) | 2012-12-17 | 2018-02-06 | Abbott Point Of Care Inc. | Portable clinical analysis system for immunometric measurement |
KR101481240B1 (en) * | 2012-12-27 | 2015-01-19 | 고려대학교 산학협력단 | Apparatus and method for monitoring platelet function and drug response in a microfluidic-chip |
CN103487377B (en) * | 2013-10-11 | 2016-03-09 | 江苏英诺华医疗技术有限公司 | A kind of detector for coagulation function of whole blood and detection method |
US9452199B2 (en) * | 2014-01-17 | 2016-09-27 | General Electric Company | Platelet activation and growth factor release using electric pulses |
US9354243B2 (en) | 2014-05-05 | 2016-05-31 | Haemonetics Corporation | Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis in a blood sample using viscoelastic analysis |
PE20170737A1 (en) | 2014-09-09 | 2017-07-04 | Perosphere Inc | CHIP-BASED MICROFLUID UNIVERSAL COAGULATION ANALYSIS |
US9561184B2 (en) | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
US10539579B2 (en) | 2014-09-29 | 2020-01-21 | C A Casyso Gmbh | Blood testing system and method |
US10175225B2 (en) | 2014-09-29 | 2019-01-08 | C A Casyso Ag | Blood testing system and method |
JP6833703B2 (en) * | 2014-11-14 | 2021-02-24 | コラ ヘルスケア インコーポレイテッド | Stroke subtype determination device and method |
US9726647B2 (en) | 2015-03-17 | 2017-08-08 | Hemosonics, Llc | Determining mechanical properties via ultrasound-induced resonance |
CN105403691B (en) * | 2016-01-01 | 2017-08-18 | 赛奥生物科技(青岛)有限公司 | A kind of Blood Kit analysis system |
CN106198943B (en) * | 2016-08-16 | 2019-11-12 | 中国科学院苏州生物医学工程技术研究所 | A device for hemodynamic analysis |
US11596948B2 (en) * | 2016-11-17 | 2023-03-07 | Enicor Gmbh | Coated articles for blood coagulation testing and methods of preparing the same |
CN115561306A (en) | 2017-04-20 | 2023-01-03 | 海默索尼克斯有限公司 | Disposable system for hemostatic function analysis |
WO2020027741A1 (en) * | 2018-07-29 | 2020-02-06 | Koc Universitesi | Microfluidic thromboelastometry instrument |
US20210260589A1 (en) * | 2020-02-26 | 2021-08-26 | Emmanuel Mpock | Method and Apparatus for Measuring Blood Coagulation |
KR102414376B1 (en) * | 2020-05-26 | 2022-06-29 | 고려대학교 산학협력단 | Blood test apparatus |
US12246266B2 (en) | 2022-09-15 | 2025-03-11 | Velico Medical, Inc. | Disposable for a spray drying system |
US11998861B2 (en) | 2022-09-15 | 2024-06-04 | Velico Medical, Inc. | Usability of a disposable for a spray drying plasma system |
US12083447B2 (en) | 2022-09-15 | 2024-09-10 | Velico Medical, Inc. | Alignment of a disposable for a spray drying plasma system |
US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
US11975274B2 (en) | 2022-09-15 | 2024-05-07 | Velico Medical, Inc. | Blood plasma product |
US12246093B2 (en) | 2022-09-15 | 2025-03-11 | Velico Medical, Inc. | Methods for making spray dried plasma |
CN117783546A (en) * | 2023-11-22 | 2024-03-29 | 苏州科技大学 | Bedside blood type detection device based on laser and detection method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5181415A (en) | 1990-07-20 | 1993-01-26 | Serbio | Apparatus for detecting a change of viscosity by measuring a relative slip, in particular for detecting the coagulation rate of blood |
US5838515A (en) * | 1996-04-30 | 1998-11-17 | Quantum Corporation | PWM/linear driver for disk drive voice coil actuator |
US6060323A (en) * | 1997-06-27 | 2000-05-09 | Hemosense, Inc. | Method and device for measuring blood coagulation or lysis by viscosity changes |
US20040175296A1 (en) | 1999-11-15 | 2004-09-09 | Opalsky Cindra A. Widrig | Apparatus and method for assaying coagulation in fluid samples |
US7005857B2 (en) * | 2000-12-19 | 2006-02-28 | Lifescan Scotland Limited | Device for measuring blood coagulation and method thereof |
US7074582B2 (en) | 2000-10-27 | 2006-07-11 | Biomerieux, Inc. | Method for assessing coagulation |
US7361306B2 (en) | 2002-04-18 | 2008-04-22 | Antonio Bote Bote | Device and method for measuring coagulation time and platelet activity |
US7399637B2 (en) | 2004-04-19 | 2008-07-15 | Medtronic, Inc. | Blood coagulation test cartridge, system, and method |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023A (en) * | 1847-03-20 | Stocking-loom | ||
JPH0743388B2 (en) * | 1990-05-29 | 1995-05-15 | 日立化成工業株式会社 | Method for measuring gelation reaction associated with blood coagulation, measuring device and measuring element |
DE60034479T2 (en) * | 1999-11-15 | 2007-12-27 | I-Stat Corporation | DEVICE AND METHOD FOR DETERMINING COAGULATION IN LIQUID SAMPLES |
WO2004093641A2 (en) * | 2003-04-16 | 2004-11-04 | Drexel University | Acoustic blood analyzer for assessing blood properties |
US20040228766A1 (en) * | 2003-05-14 | 2004-11-18 | Witty Thomas R. | Point of care diagnostic platform |
CN2916635Y (en) * | 2006-06-09 | 2007-06-27 | 姚冬 | Blood coagulation analysis tester |
JP4675946B2 (en) * | 2007-09-07 | 2011-04-27 | 独立行政法人産業技術総合研究所 | Viscosity measuring device |
-
2010
- 2010-12-17 MX MX2012007084A patent/MX2012007084A/en active IP Right Grant
- 2010-12-17 CN CN201080055503.9A patent/CN102687009B/en active Active
- 2010-12-17 US US12/971,013 patent/US8450078B2/en active Active
- 2010-12-17 CA CA2780492A patent/CA2780492C/en active Active
- 2010-12-17 JP JP2012544860A patent/JP5655091B2/en active Active
- 2010-12-17 BR BR112012014421A patent/BR112012014421B8/en active IP Right Grant
- 2010-12-17 EP EP20100838275 patent/EP2513647B1/en active Active
- 2010-12-17 ES ES10838275.5T patent/ES2543099T3/en active Active
- 2010-12-17 WO PCT/US2010/060911 patent/WO2011075614A2/en active Application Filing
- 2010-12-17 PE PE2012000844A patent/PE20121723A1/en active IP Right Grant
- 2010-12-17 AU AU2010330861A patent/AU2010330861B2/en active Active
-
2012
- 2012-06-15 NI NI201200109A patent/NI201200109A/en unknown
- 2012-06-15 HN HN2012001269A patent/HN2012001269A/en unknown
- 2012-06-15 CR CR20120326A patent/CR20120326A/en unknown
- 2012-06-18 EC ECSP12011981 patent/ECSP12011981A/en unknown
- 2012-06-20 CO CO12103321A patent/CO6551732A2/en active IP Right Grant
-
2013
- 2013-01-21 HK HK13100873.7A patent/HK1173497A1/en unknown
- 2013-05-20 US US13/897,712 patent/US9063161B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5181415A (en) | 1990-07-20 | 1993-01-26 | Serbio | Apparatus for detecting a change of viscosity by measuring a relative slip, in particular for detecting the coagulation rate of blood |
US5838515A (en) * | 1996-04-30 | 1998-11-17 | Quantum Corporation | PWM/linear driver for disk drive voice coil actuator |
US6060323A (en) * | 1997-06-27 | 2000-05-09 | Hemosense, Inc. | Method and device for measuring blood coagulation or lysis by viscosity changes |
US20040175296A1 (en) | 1999-11-15 | 2004-09-09 | Opalsky Cindra A. Widrig | Apparatus and method for assaying coagulation in fluid samples |
US7074582B2 (en) | 2000-10-27 | 2006-07-11 | Biomerieux, Inc. | Method for assessing coagulation |
US7005857B2 (en) * | 2000-12-19 | 2006-02-28 | Lifescan Scotland Limited | Device for measuring blood coagulation and method thereof |
US7361306B2 (en) | 2002-04-18 | 2008-04-22 | Antonio Bote Bote | Device and method for measuring coagulation time and platelet activity |
US7399637B2 (en) | 2004-04-19 | 2008-07-15 | Medtronic, Inc. | Blood coagulation test cartridge, system, and method |
Non-Patent Citations (3)
Title |
---|
Goto et al. "Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets", JBC, 1995, 270(40): 23352-23361. * |
Horn, "Addition of a polarizing microscope to the Weissenberg Rheogoniometer", Rev. Sce. Instrum., 1979,659-661. * |
Moake et al. "Invovement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation", J. Clin. Invest., 1986, 78:1456-1461. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240069043A1 (en) * | 2009-12-18 | 2024-02-29 | Entegrion, Inc. | Portable coagulation monitoring devices, systems, and methods |
US9816955B2 (en) | 2011-12-26 | 2017-11-14 | Panasonic Healthcare Holdings Co., Ltd. | Liquid sample measuring system and measuring device |
US10473608B2 (en) | 2011-12-26 | 2019-11-12 | Phc Holdings Corporation | Liquid sample measuring system and measuring device |
US10739239B1 (en) * | 2013-10-28 | 2020-08-11 | Ifirst Medical Technologies, Inc. | Rotating magnetic disc medical analyzer and coagulation profiler |
US10823743B1 (en) * | 2013-10-28 | 2020-11-03 | Ifirst Medical Technologies, Inc. | Methods of measuring coagulation of a biological sample |
US11598707B1 (en) | 2013-10-28 | 2023-03-07 | Ifirst Medical Technologies, Inc. | Medical analyzer and coagulation profiler |
US11788941B1 (en) | 2013-10-28 | 2023-10-17 | Ifirst Medical Technologies, Inc. | Method of using disposable BioMEMS coagulation profiling cartridge |
US12203833B1 (en) | 2013-10-28 | 2025-01-21 | Ifirst Medical Technologies, Inc. | Medical analyzer and coagulation profiler with tracked oscillating disc |
US12203834B1 (en) | 2013-10-28 | 2025-01-21 | Ifirst Medical Technologies, Inc. | Disposable BioMEMS coagulation profiling cartridge with a tracked oscillating disc |
WO2015073941A1 (en) | 2013-11-15 | 2015-05-21 | Entegrion, Inc. | Portable coagulation monitoring devices, systems, and methods |
US11378507B2 (en) * | 2016-11-15 | 2022-07-05 | Haemograph Pty Ltd. | Rheometer and method for the use thereof |
US11879821B2 (en) | 2016-11-15 | 2024-01-23 | Haemograph Pty Ltd. | Rheometer and method for the use thereof |
US12019041B2 (en) | 2018-11-20 | 2024-06-25 | Xatek, Inc. | Portable dielectric spectroscopy device |
US12277814B2 (en) | 2020-01-29 | 2025-04-15 | Ifirst Medical Technologies, Inc. | Medical analyzer and diagnostic sample profiler |
Also Published As
Publication number | Publication date |
---|---|
ES2543099T3 (en) | 2015-08-14 |
NI201200109A (en) | 2013-02-15 |
HN2012001269A (en) | 2014-12-01 |
EP2513647A2 (en) | 2012-10-24 |
CA2780492C (en) | 2018-07-17 |
US20130267017A1 (en) | 2013-10-10 |
US20110151491A1 (en) | 2011-06-23 |
MX2012007084A (en) | 2012-10-15 |
PE20121723A1 (en) | 2012-12-11 |
BR112012014421A2 (en) | 2017-12-19 |
ECSP12011981A (en) | 2012-08-31 |
WO2011075614A2 (en) | 2011-06-23 |
CR20120326A (en) | 2012-09-24 |
BR112012014421B8 (en) | 2021-07-27 |
CA2780492A1 (en) | 2011-06-23 |
US9063161B2 (en) | 2015-06-23 |
CO6551732A2 (en) | 2012-10-31 |
EP2513647A4 (en) | 2013-09-04 |
AU2010330861B2 (en) | 2013-09-26 |
BR112012014421B1 (en) | 2021-02-02 |
HK1173497A1 (en) | 2013-05-16 |
JP5655091B2 (en) | 2015-01-14 |
EP2513647B1 (en) | 2015-04-22 |
CN102687009B (en) | 2014-07-16 |
WO2011075614A3 (en) | 2011-10-13 |
JP2013515238A (en) | 2013-05-02 |
AU2010330861A1 (en) | 2012-05-31 |
CN102687009A (en) | 2012-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8450078B2 (en) | Portable coagulation monitoring device and method of assessing coagulation response | |
US7857761B2 (en) | Acoustic blood analyzer for assessing blood properties | |
US11680940B2 (en) | Characterization of blood hemostasis and oxygen transport parameters | |
KR100237946B1 (en) | Apparatus for assaying viscosity changes in fluid samples and method of conducting the same | |
US20040131500A1 (en) | Device and method for evaluating platelets | |
US11768210B2 (en) | Portable coagulation monitoring devices, systems, and methods | |
Sanak et al. | Assessment of hemocompatibility of materials with arterial blood flow by platelet functional tests | |
JP6503605B2 (en) | Portable device, system and method for blood coagulation monitoring | |
AU2013234363B2 (en) | Portable coagulation monitoring device | |
US20240069043A1 (en) | Portable coagulation monitoring devices, systems, and methods | |
Hartmann et al. | diagnostics MDPI | |
Yaraş | A portable blood coagulation time measurement platform with fiber-optic based disposable cartridge | |
Nabavi | Portable devices for In-Vitro characterization based on ultrasound | |
Metref et al. | Portable Technologies for Self-Monitoring of Coagulation Time: A Review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ENTEGRION, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENNIS, ROBERT GLENN;FISCHER, THOMAS H.;DACORTA, JOSEPH ANTHONY;SIGNING DATES FROM 20110104 TO 20110106;REEL/FRAME:025644/0526 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, MARYLAND Free format text: SECURITY INTEREST;ASSIGNOR:ENTEGRION, INC.;REEL/FRAME:032913/0959 Effective date: 20140401 |
|
AS | Assignment |
Owner name: HEALTHCARE FINANCIAL SOLUTIONS, LLC, MARYLAND Free format text: ASSIGNMENT OF SECURITY INTEREST;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION;REEL/FRAME:038754/0718 Effective date: 20151109 |
|
AS | Assignment |
Owner name: SOLAR CAPITAL LTD., AS SUCCESSOR AGENT, NEW YORK Free format text: ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS RETIRING AGENT;REEL/FRAME:039079/0955 Effective date: 20160616 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: ENTEGRION INC., NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SOLAR CAPITAL LTD.;REEL/FRAME:062790/0143 Effective date: 20170328 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |